Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 1090016

Left ventricular bypass.

C N Barnard·J G Losman
View original source ↗Export metadata ↓

Abstract

The removal of the patient's own diseased heart in order to perform a total cardiac transplantation has several disadvantages. A new technique for bypassing the patient's diseased left ventricle by using a cardiac allograft has been developed in our laboratory and applied clinically in 2 patients. This technique carried no direct surgical mortality, and no complications resulting from the patient's own heart being left in situ have been observed thus far. The presence of a second heart lying partly in the anterior mediastinum and partly in the right pleural space appeared to have no deleterious effects. Several advantages over the conventional transplant have been noted and are discussed.

Explore related subjects

AortaCardiac CatheterizationCardiopulmonary BypassCoronary DiseaseElectrocardiographyHeartHeart AtriaHeart FailureHeart TransplantationHeart VentriclesHemodynamicsHumansMaleMiddle AgedPulmonary ArteryRheumatic Heart DiseaseTissue DonorsTransplantation, HomologousVena Cava, InferiorVena Cava, SuperiorJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C N Barnard, J G Losman. 1975-03-01. Left ventricular bypass.. https://pubmed.ncbi.nlm.nih.gov/1090016/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.

Micro- and macroangiopathy are major causes of morbidity and mortality in patients with diabetes. Our aim was to characterize IGF-I receptor (IGF-IR) and insulin receptor (IR) in human micro- and macrovascular endothelial cells. Cultured human dermal microvascular endothelial cells (HMVEC) and human aortic endothelial cells (HAEC) were used. Gene expression was measured by quantitative real-time RT-PCR and receptor protein by ligand-binding assay. Phosphorylation of IGF-IR beta-subunit was analyzed by immunoprecipitation and Western blot. Glucose metabolism and DNA synthesis was assessed using [(3)H]glucose and [(3)H]thymidine incorporation, respectively. We detected gene expression of IGF-IR and IR in HAEC and HMVEC. IGF-IR gene expression was severalfold higher than that of IR. The specific binding of (125)I-IGF-I was higher than that of (125)I-insulin in HAEC and HMVEC. Insulin and the new, long-acting insulin analog glargine interacted with the IGF-IR with thousand- and hundred-fold less potency than IGF-I itself. Phosphorylation of the IGF-IR beta-subunit was shown in HAEC for IGF-I (10(-8) M) and insulin (10(-6) M) and in HMVEC for IGF-I and glargine (10(-8) M, 10(-6) M). IGF-I 10(-7) M stimulated incorporation of [(3)H]thymidine into DNA, and 10(-9)-10(-7) M also the incorporation of [(3)H]glucose in HMVEC, whereas glargine and insulin had no significant effects at 10(-9)-10(-7) M. Human micro- and macrovascular endothelial cells express more IGF-IR than IR. IGF-I and high concentrations of glargine and insulin activates the IGF-IR. Glargine has a higher affinity than insulin for the IGF-IR but probably has no effect on DNA synthesis at concentrations reached in vivo.

Aorta↗